Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onradivir in acute uncomplicated influenza A
NCT07229820Phase 3Active, not recruiting
- Sponsor
- Raynovent Biotech
- Start
- Nov 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anlatrelvir in Influenza A (IAV), sponsored by Raynovent Biotech. Started Nov 2025; status: active, not recruiting.
02
Drugs
anlatrelvir
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT07229820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229820.